



Thomas Koehnke

Postdoctoral Research Fellow, Stanford Cancer Center

Bio

PROFESSIONAL EDUCATION

- Doctor of Medicine, Freie Universitat Berlin (2015)
- Staatsexamen, University of Göttingen (2010)

Publications

PUBLICATIONS

- **Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2.** *The Journal of clinical investigation*
Dutta, R., Zhang, T. Y., Köhnke, T., Thomas, D., Linde, M., Gars, E., Stafford, M., Kaur, S., Nakauchi, Y., Yin, R., Azizi, A., Narla, A., Majeti, et al
2020
- **Response assessment in acute myeloid leukemia by flow cytometry supersedes cytomorphology at time of aplasia, amends cases without molecular residual disease marker and serves as an independent prognostic marker at time of aplasia and post-induction** *HAEMATOLOGICA*
Koehnke, T., Buecklein, V., Rechkemmer, S., Schneider, S., Rothenberg-Thurley, M., Metzeler, K. H., Sauerland, M., Hiddemann, W., Spiekermann, K., Subklewe, M.
2019; 104 (11): E510–E513
- **Asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia** *LEUKEMIA & LYMPHOMA*
Lanvers-Kaminsky, C., Niemann, A., Eveslage, M., Beck, J., Koehnke, T., Martin, S., de Wit, M., Spriewald, B., Hauspurg, H., Hoelzer, D., Boos, J., Goekbuget, N.
2020; 61 (1): 138–45
- **A Role for Lipid Mediators in Acute Myeloid Leukemia** *INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES*
Loew, A., Koehnke, T., Rehbeil, E., Pietzner, A., Weylandt, K.
2019; 20 (10)
- **Barcoded Clonal Tracking of CRISPR-Cas9 and rAAV6-Mediated Gene Targeting in Human Hematopoietic Stem and Progenitor Cells**
Dever, D. P., Sharma, R., Lee, C. M., Aziz, A., Koehnke, T., Camarena, J., Pan, Y., Zhao, F., Bao, G., Majeti, R., Porteus, M.
CELL PRESS.2019: 5
- **Data mining for mutation-specific targets in acute myeloid leukemia.** *Leukemia*
Benard, B., Gentles, A. J., Kohnke, T., Majeti, R., Thomas, D.
2019
- **Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML.** *Leukemia*
Haubner, S., Perna, F., Köhnke, T., Schmidt, C., Berman, S., Augsberger, C., Schnorfeil, F. M., Krupka, C., Lichtenegger, F. S., Liu, X., Kerbs, P., Schneider, S., Metzeler, et al
2019; 33 (1): 64–74
- **Azacitidine and Ascorbate Inhibit the Competitive Outgrowth of Human TET2 Mutant HSPCs in a Xenograft Model of Pre-Leukemia**

Nakauchi, Y., Thomas, D., Sharma, R., Corces, M., Reinisch, A., Cruz, D., Koehnke, T., Karigane, D., Fan, A., Majeti, R.
AMER SOC HEMATOLOGY.2018

- **Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.** *Leukemia*
Rothenberg-Thurley, M., Amler, S., Goerlich, D., Köhnke, T., Konstandin, N. P., Schneider, S., Sauerland, M. C., Herold, T., Hubmann, M., Ksienzyk, B., Zellmeier, E., Bohlander, S. K., Subklewe, et al
2018; 32 (7): 1598–1608
- **Diagnosis of CLL revisited: increased specificity by a modified five-marker scoring system including CD200.** *British journal of haematology*
Köhnke, T., Wittmann, V. K., Bücklein, V. L., Lichtenegger, F., Pasalic, Z., Hiddemann, W., Spiekermann, K., Subklewe, M.
2017; 179 (3): 480–87
- **Recent developments in immunotherapy of acute myeloid leukemia.** *Journal of hematology & oncology*
Lichtenegger, F. S., Krupka, C., Haubner, S., Köhnke, T., Subklewe, M.
2017; 10 (1): 142
- **Targeting CD157 in AML using a novel, Fc-engineered antibody construct.** *Oncotarget*
Krupka, C., Lichtenegger, F. S., Köhnke, T., Bögeholz, J., Bücklein, V., Roiss, M., Altmann, T., Do, T. U., Dusek, R., Wilson, K., Bisht, A., Terrett, J., Aud, et al
2017; 8 (22): 35707–17
- **Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.** *Leukemia*
Krupka, C., Kufer, P., Kischel, R., Zugmaier, G., Lichtenegger, F. S., Köhnke, T., Vick, B., Jeremias, I., Metzeler, K. H., Altmann, T., Schneider, S., Fiegl, M., Spiekermann, et al
2016; 30 (2): 484–91
- **Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab.** *Journal of hematology & oncology*
Köhnke, T., Krupka, C., Tischer, J., Knösel, T., Subklewe, M.
2015; 8: 111
- **Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings.** *Annals of hematology*
Tischer, J., Engel, N., Fritsch, S., Prevalsek, D., Hubmann, M., Schulz, C., Zoellner, A. K., Bücklein, V., Reibke, R., Mumm, F., Rieger, C. T., Hill, W., Ledderose, et al
2015; 94 (10): 1677–88
- **Immunotherapy for Acute Myeloid Leukemia.** *Seminars in hematology*
Lichtenegger, F. S., Krupka, C., Köhnke, T., Subklewe, M.
2015; 52 (3): 207–14
- **Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse.** *Leukemia*
Köhnke, T., Sauter, D., Ringel, K., Hoster, E., Laubender, R. P., Hubmann, M., Bohlander, S. K., Kakadia, P. M., Schneider, S., Dufour, A., Sauerland, M. C., Berdel, W. E., Büchner, et al
2015; 29 (2): 377–86
- **Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.** *Haematologica*
Hubmann, M., Köhnke, T., Hoster, E., Schneider, S., Dufour, A., Zellmeier, E., Fiegl, M., Braess, J., Bohlander, S. K., Subklewe, M., Sauerland, M. C., Berdel, W. E., Büchner, et al
2014; 99 (8): 1317–25
- **CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.** *Blood*
Krupka, C., Kufer, P., Kischel, R., Zugmaier, G., Bögeholz, J., Köhnke, T., Lichtenegger, F. S., Schneider, S., Metzeler, K. H., Fiegl, M., Spiekermann, K., Baeuerle, P. A., Hiddemann, et al
2014; 123 (3): 356–65
- **Acetylsalicylic Acid reduces the severity of dextran sodium sulfate-induced colitis and increases the formation of anti-inflammatory lipid mediators.** *BioMed research international*
Köhnke, T., Gomolka, B., Bilal, S., Zhou, X., Sun, Y., Rothe, M., Baumgart, D. C., Weylandt, K. H.
2013; 2013: 748160

- **Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC).** *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*
Di Gioia, D., Heinemann, V., Nagel, D., Untch, M., Kahlert, S., Bauerfeind, I., Koehnke, T., Stieber, P.
2011; 32 (4): 777–85
- **Reduction of inflammation and chronic tissue damage by omega-3 fatty acids in fat-1 transgenic mice with pancreatitis.** *Biochimica et biophysica acta*
Weylandt, K. H., Nadolny, A., Kahlke, L., Köhnke, T., Schmöcker, C., Wang, J., Lauwers, G. Y., Glickman, J. N., Kang, J. X.
2008; 1782 (11): 634–41